492 results about "Ribose" patented technology

The invention discloses application of a ganoderma lucidum strain SS30 in preparation of a product for treating cancers, and belongs to the technical field of biology. The invention provides ganoderma lucidum strain SS30 mycelium polysaccharide. The ganoderma lucidum strain SS30 mycelium polysaccharide is prepared from glucose, galactose, mannose, fucose, xylose, arabinose, rhamnose, glucuronic acid, glucosamine, ribose and lacturonic acid. The polysaccharide has a remarkable effect of inhibiting transplantable pancreatic cancer and primary colorectal cancer, can achieve the effect of treating cancer by improving the immune function and reducing the oxidation product generation level, provides a new material for development and utilization of lucid ganoderma and products thereof, and has a wide application prospect. And a research basis is provided for research and development of cancer-related drugs and research of a cancer treatment mechanism.

The invention provides a uracil production strain and a construction method and application thereof.According to the strain, on an E.coli UR14 genome by means of a CRIPSR / Cas9 gene editing technology, firstly, psuG genes, preTA genes, rutA genes and upp genes are knocked out, so that decomposition of uracil is blocked; then, a uridine phosphorylase gene udp and a pyrimidine-5 '-nucleotide nucleotidase gene ppnN are subjected to overexpression, and synthesis and accumulation of uracil are synergistically enhanced; and finally, overexpression of the ribose phosphate mutase gene pgm further enhances the conversion of a by-product ribose phosphate 1-precursor 5-ribose phosphate 1-pyrophosphate and improves the carbon utilization rate, and the obtained strain has good genetic stability and high fermentation yield, can stably produce uracil, and has wide application prospects.

The present invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor 5-[[(2S)-1-(3-oxo-3-[4-[5-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4-(trifluoromethyl)-2,3-dihydropyridazin-3-one, and salts thereof, including methods of preparation thereof, where the inhibitor is useful in the treatment of cancer.

The invention belongs to the technical field of stem cell biological preparations, and particularly relates to an anti-aging compound preparation based on stem cells and application of the anti-aging compound preparation in delaying skin aging. The composition is composed of an inner water phase, a middle oil phase and an outer water phase, wherein the inner water phase is prepared from the following components: stem cell exosomes, hyaluronic acid, nicotinamide ribose, trehalose, mannitol, glycine and a citric acid buffer solution; the medium oil phase is prepared from the following components: medium chain triglyceride, shea butter, vitamin E succinate, PEG (Polyethylene Glycol) modified ceramide NP and cholesterol succinic acid monoester; the external water phase is prepared from the following components: polydatin, cellulose nanocrystals and an emulsifying agent. On the basis of a W / O / W emulsion system, a multi-layer anti-aging mechanism is constructed by utilizing a three-dimensional delivery framework of an inner water phase, an oil phase and an outer water phase and space-time synergy of active ingredients, the exosome permeation efficiency is improved through microneedle introduction, and the anti-oxidation and barrier repair effects are achieved by using multiple ingredients.

Disclosed is a compound of formula (I), its pharmaceutically acceptable salt or pro-drug thereof, where R1, R2, X, L1, L2, L3, L4, L5, and R are as disclosed herein. The compounds disclosed herein can have poly[ADP-Ribose) polymerase 1 (PARP- 1) inhibitory activity. As such, the compounds and compositions containing the compounds, as disclosed herein, can have use for treatment of diseases associated with PARP-1.

The invention discloses temozolomide derivatives or pharmaceutically acceptable salts, crystal forms and solvates, wherein the structure of the temozolomide derivatives is shown as a formula I in the specification. According to the temozolomide derivative disclosed by the invention, damage caused by repairing temozolomide by cells is prevented by inhibiting PARP1 protein, so that the purpose of improving the overall anti-glioblastoma effect is achieved. The invention further discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate to preparation of a PARP1 inhibitor. The invention also discloses application of the temozolomide derivative or the pharmaceutically acceptable salt, the crystal form and the solvate in preparation of medicines for preventing and / or treating tumors. The invention also discloses a pharmaceutical composition, and the pharmaceutical composition takes a safe and effective amount of temozolomide derivative or pharmaceutically acceptable salt, crystal form and solvate as effective components or main effective components, and is prepared into a pharmaceutically acceptable dosage form together with a pharmaceutically acceptable carrier.

The invention belongs to the technical field of biochemistry, and particularly relates to application of nicotinamide ribose malate in light aging resistance. The invention provides an application of nicotinamide ribose malate in light aging resistance, and particularly relates to an application of nicotinamide ribose malate in quantitative light aging resistance of human immortalized keratinocytes. According to the invention, 0.375 mg / mL to 1.50 mg / mL of nicotinamide ribose malate is used for resisting light aging of the skin, and the light aging resisting effect is improved by 12.13% to 35.09%. Particularly, 1.50 mg / mL of nicotinamide ribose malate is used for resisting light aging of human immortalized keratinocytes, the light aging resisting effect is improved by 35.09%, and the light aging resisting effect is obvious.

The present disclosure provides linker compounds of Formula (I) or (II):pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. The present disclosure also relates to uses of the linker compounds, scaffolds, and conjugates, e.g., in delivering nucleic acid and / or treating or preventing diseases.

The invention discloses a low-temperature preservation method of a prepared meat product, and belongs to the technical field of food processing. In order to solve the technical problems that in the low-temperature storage process of the conditioned meat product, microorganism control is not thorough, secondary pollution and fat oxidation aggravation are caused by accumulation of high-oxygen conditioned packaging condensate water, and texture damage is caused by ultrahigh-pressure treatment, metal ion catalysis is blocked through phytic acid pretreatment, oxidation is inhibited through composite antioxidant vacuum rolling and kneading, and the quality of the conditioned meat product is improved. Gradient ultrahigh pressure destroys microbial structures in stages, citric acid and a D-ribose buffer solution block damaged thalli from repairing, a composite packaging bag is lined with a hygroscopic film and filled with high-oxygen mixed gas to maintain meat color and adsorb condensate water, and finally, the composite packaging bag is deeply frozen to form a microcrystalline structure and then transferred to an ice-temperature environment for storage. The method realizes microbial safety control under the condition of no chemical preservative, effectively maintains the cell integrity of meat products, reduces juice loss and fat oxidation, prolongs the shelf life and maintains the eating quality.

The invention relates to the technical field of organ transplantation, and discloses organ preserving fluid, application and organ dynamic supercooling perfusion equipment. The organ preserving fluid is prepared from ribose, glucose, mannitol, lidocaine, adenosine, a high-molecular polymer, L-proline, trehalose, inorganic salt and organic salt. The high-molecular polymer comprises one of hydroxyethyl starch, polyethylene glycol and albumin. According to the organ preserving fluid disclosed by the invention, the freezing point of the perfusate is reduced through the micromolecular cryoprotectant, and meanwhile, the micromolecular cryoprotectant and the high-molecular polymer jointly inhibit formation and growth of ice crystals; the problem of liquid preservation at the temperature below zero is solved from the two dimensions of physics (reducing the freezing point and inhibiting ice crystals) and biology (maintaining cell viability), and feasibility is provided for long-time low-temperature transfer and transplantation of organs. The preserving fluid can be used for static preservation or perfusion preservation of various organs such as kidney, liver, heart, pancreas, lung, small intestine, skin and the like.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The invention discloses a cosmetic composition with a multi-cell energy improving effect and application of the cosmetic composition. The cosmetic composition is obtained by compounding the ribose, the artemia extract and the fructose trisodium diphosphate, the components have a remarkable synergistic effect, and oxidation resistance can be achieved after compounding; mitochondria is protected; promoting skin barrier generation or enhancing skin barrier defense; preserving moisture; wrinkle resistance; therefore, the effect of integrating multiple effects in a real sense is realized, and the use requirements of various types of consumer groups are met.

In one aspect, the disclosed technology relates to nanopore sequencing with a polynucleotide including a plurality of ribonucleotides, wherein each ribonucleotide comprises a cyclic loop between two positions of the ribonucleotide, wherein the cyclic loop comprises a spacer or reporter moiety corresponding to the identity of the ribonucleotide, one or more linkers, and optionally one or more arresting constructs. The cyclic loop may be selectively cleaved in a ribose-mediated pathway to cause cleavage at the 5' P-O bond of the phosphate backbone.

The invention relates to the technical field of microbial metabolism engineering, and discloses a genetically engineered bacterium for high-yield L-histidine as well as a construction method and application of the genetically engineered bacterium. A nucleoside triphosphate pyrophosphate hydrolase coding gene mazG gene and a flagellin synthesis gene flhC gene are knocked out at the same time, an o-aminobenzoic acid phosphoribosyltransferase coding gene trpD gene and a ribulose phosphate 3-isomerase coding gene rpe gene are knocked down, and the recombinant protein is obtained. A ribose-5-phosphate isomerase gene coding rpiA gene and a lysine exponential coding gene lysE gene are overexpressed, and a promoter of 6-phosphoglucose isomerase pgi is replaced by a PfliC promoter, so that key substances for synthesis of L-histidine can be effectively accumulated, the fermentation yield of L-histidine is greatly increased, and compared with an initial strain, the yield of L-histidine is increased by 33.3%.

The preparation method of the locked nucleic acid intermediate D-ribofuranose derivative, provided by the invention, is simple in steps, stable in process, high in selectivity and easy for industrial production, and has a relatively good application prospect. According to the preparation method, the yield and the purity can be greatly improved, the economic cost is reduced, steps are shortened, multiple operation modes are simplified, the amount of organic waste liquid is remarkably reduced, materials and process conditions with safety risks are eliminated, operation with serious equipment loss is avoided, and the process conditions and the result are stable.

The present invention discloses the use of a nonspecific 5'-nucleotidase in the preparation of nicotinamide riboside. The nonspecific 5'-nucleotidase is selected from a nonspecific 5'-nucleotidase derived from Shewanella sp. HN-41. The nonspecific 5'-nucleotidase of the present invention can efficiently catalyze the hydrolysis of high-concentration nicotinamide mononucleotide (NMN) to produce nicotinamide riboside (NR), exhibits high enzymatic activity, and has value for industrial application.

The invention relates to a plant having an increased proportion of edible biomass resulting from genetic modification of gene that encodes a poly(adenosine 5′-diphosphate (ADP)-Ribose) Polymerase (PARP) enzyme.

The invention discloses a culture method for hypoxia culture of umbilical cord mesenchymal stem cells, which comprises the following steps: hypoxia pre-adaptive culture: inoculating umbilical cord mesenchymal stem cells in a culture medium containing bFGF (basic fibroblast growth factor), glutathione, astragalus polysaccharide and salidroside, and transferring the umbilical cord mesenchymal stem cells into a 5% O2 environment after the umbilical cord mesenchymal stem cells are preliminarily adhered to the wall in a normal oxygen environment; performing low-oxygen enrichment culture: replacing a second culture medium containing astragalus polysaccharide, salidroside, D-ribose, sodium pyruvate and D-glucose, and promoting efficient cell proliferation under 2% O2; performing function strengthening culture: adding tanshinone IIA and GSK-269962A, inducing cells to secrete VEGF under 1% O2, and maintaining high dryness. According to the method, through the synergistic effect of the three-stage gradient oxygen concentration and the specific serum-free culture medium, the cell proliferation multiple is remarkably increased, the total apoptosis rate is reduced, VEGF secretion is promoted, the multidirectional differentiation potential is reserved, the culture method is standardized in operation, the serum-free culture medium is definite in component, and a high-quality stem cell culture scheme is provided for the field of regenerative medicine.

The present invention is directed to methods for the use of 5'-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing VEGF modulated diseases or conditions.

A modular CRISPR-Cas system for ribonucleoprotein (RNP) delivery is provided, the CRISPR-Cas system comprising a CRISPR-Cas protein fused to a first binding peptide and a functional protein fused to a second binding peptide, where the first binding peptide and the second binding peptide are configured to bind to each other and define a binding peptide pair. Also provided are methods of assembling the CRISPR-Cas complexes for the delivery of ribonucleoprotein (RNP) and the CRISPR-Cas complexes, as well as the use of the modular CRISPR-Cas systems or CRISPR-Cas complexes for the modification of the genome of an organism.

The invention provides a method for cultivating anti-aging glutinous highland barley, highland barley starch as well as a preparation method and application of the highland barley starch, and particularly relates to a method for improving the starch quality character of an existing high-quality glutinous highland barley variety, in particular to a method for cultivating anti-aging glutinous highland barley by utilizing a gene editing technology without exogenous DNA (Deoxyribose Nucleic Acid) integration. A method for fixed-point knockout of an SSIIa gene to cultivate an anti-aging glutinous highland barley new strain under the background of a "Zhengnongglutinous 232" variety comprises the following steps: providing an acceptor material derived from a highland barley variety "Zhengnongglutinous 232" with a glutinous character, and deleting a Wx gene function of the "Zhengnongglutinous 232"; the method comprises the following steps: assembling guide RNA (Ribonucleic Acid) designed aiming at an SSIIa gene and Cas9 protein in vitro to form a ribonucleoprotein RNP complex; introducing the RNP complex into cells of an acceptor material so as to enable Cas9 protein to generate double-chain breakage at a target site of the SSIIa gene; carrying out culture and plant regeneration on the introduced cells to obtain a T0-generation plant of which the SSIIa gene is edited; and screening plants with the function loss of the SSIIa gene, wherein the plants keep the glutinous character of adult agricultural glutinous 232.

The invention relates to lipid nanoparticles for fish in-vivo skin gene editing and application of the lipid nanoparticles, and belongs to the technical field of fish gene editing. The lipid nanoparticle for fish in-vivo skin gene editing comprises a gene editing element and a lipid layer, wherein the lipid layer wraps the surface of the gene editing element; the gene editing element is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR associated protein 9) ribonucleoprotein compound or nucleic acid for coding the compound; the lipid nanoparticle carrier comprises ionizable cationic lipid, auxiliary lipid, cholesterol, pegylated lipid and permanent cationic lipid, and the lipid nanoparticle carrier comprises the following components in parts by mole: 15 parts of ionizable cationic lipid, 25-30 parts of auxiliary lipid, 30 parts of cholesterol, 3 parts of pegylated lipid and 7 parts of permanent cationic lipid. The formula is high in pertinence, high in editing efficiency, simple, convenient and safe to operate and wide in application prospect.

The invention discloses an umbilical cord mesenchymal stem cell serum-free culture medium, which is composed of a basic culture medium and additive components, and the additive components comprise, by final concentration, 5-20 [mu] g / mL of astragalus polysaccharide, 0.5-2.0 [mu] g / mL of salidroside, 0.1-0.5 [mu] g / mL of tanshinone IIA, 0.1-0.3 mg / mL of sodium pyruvate, 5-15 mM of D-ribose, 3-6 mg / mL of recombinant human albumin, and 5-10 [mu] g / mL of recombinant transferrin; the invention also discloses a method for culturing umbilical cord mesenchymal stem cells under the hypoxia condition by using the serum-free culture medium. The method comprises the steps of cell inoculation, culture under the hypoxia condition, subculture, cell passage and the like. The astragalus polysaccharide, the salidroside, the tanshinone IIA, the sodium pyruvate, the recombinant human albumin and the recombinant transferrin are added into the serum-free culture medium, so that nutrition supply and function maintenance of cells under a low-oxygen condition are guaranteed, the proliferation rate and the differentiation capacity of the cultured cells are improved, the apoptosis rate of the cells is reduced, and the survival rate of the cells is increased. Wide application prospects are realized in the fields of cell culture, regenerative medicine and the like.

The utility model discloses D-ribose crystal separating and drying equipment which comprises a machine box, a rectangular frame is arranged between the left inner wall and the right inner wall of the machine box, a heating wire is arranged in the rectangular frame, a material frame is arranged on the bottom wall of the machine box, and the D-ribose crystal separating and drying equipment further comprises an air guiding mechanism and a material turning mechanism. The air guide mechanism comprises rotating shafts, a supporting plate and fans, the rotating shafts are rotationally connected to the upper sides of the left inner wall and the right inner wall of the case respectively, the supporting plate is fixedly connected between the inner side ends of the rotating shafts, and the fans which are bilaterally symmetrical are arranged in the supporting plate; the material overturning mechanism comprises a C-shaped plate, a rotating column, a support and a material scraping rod, and the C-shaped plate is slidably connected between the left end and the right end of the material frame. According to the D-ribose crystal separating and drying equipment, when D-ribose crystals are dried, air in a container is effectively circulated through swinging of a fan, meanwhile, the D-ribose crystals are overturned, and the drying efficiency of the D-ribose crystals is improved. And the D-ribose crystal is heated more uniformly, and the drying effect is better.

The present disclosure relates to biodegradable polymeric microspheres comprising a biodegradable polymer and an immunotherapeutic agent selected from the group consisting of a poly ADP ribose polymerase inhibitor (PARP inhibitor) and / or a Toll-like receptor (TLR) agonist, wherein (a) 50% of the total amount of the immunotherapeutic agent in the biodegradable polymer microspheres is released from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; (b) releasing the immunotherapeutic agent with the dry weight of 1 mg / g to 100 mg / g from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; or (c) satisfies both (a) and (b). Other aspects of the present disclosure relate to methods of using such microparticles and kits comprising such microparticles.

To provide a composition that exhibits excellent bacteriostatic performance.SOLUTION: A bacteriostatic composition comprises (A) melanoidin produced from at least one selected from xylose and ribose and at least one selected from phenylalanine and proline as a reaction substrate, and (B) a chelating agent. It is preferable that the chelating agent (B) is at least one selected from citric acid or a salt thereof and condensed phosphoric acid or a salt thereof. It is also preferable that the composition further contains at least one selected from organic acids or salts thereof other than the chelating agent. It is also preferable that the organic acid or a salt thereof is acetate.SELECTED DRAWING: None

The present disclosure provides compounds, in part, compounds having Formula (I) or Formula (II), and their use in the treatment of medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making the compounds of the present disclosure are provided. These compounds are envisaged to be modulators, e.g., inhibitors, of cyclic ADP ribohydrolase (CD38).

The present invention provides a GalNAc compound containing a ribose ring or its derivative structure and an oligonucleotide conjugate thereof. With the oligonucleotide conjugate provided by the present invention, efficient liver-targeted delivery can be achieved, improving the drug efficacy.